Vanderbilt
The researchers hope to reproduce in a prospective clinical trial the model's 70 percent to 80 percent accuracy for predicting immunotherapy response.
They are exploring a nicotine metabolite ratio that reflects variations in the CYP2A6 gene to gauge if it can ID patients who need more personalized smoking cessation interventions.
Alliance for Genomic Discovery Adds Major Biopharma Partners to Help Fund WGS-Based Biobank
Funding from AbbVie, Amgen, AstraZeneca, Bayer, and Merck will enable DeCode Genetics to sequence an additional 215,000 samples for the alliance.
Large Study of Early-Onset Colorectal Cancer Patients IDs Unique, Potentially Actionable Mutations
In younger patients, HER2 mutations were more prevalent in those who had MSI-high/TMB-high tumors, while POLE mutations were more common in MSS/TMB-high tumors, researchers reported at ASCO.
Prostate Cancer Polygenic Score Does Not Improve High-Grade Disease Prediction Over Clinical Factors
Researchers found that adding genetic risk score data did not improve their ability to predict aggressive prostate cancer cases over conventional risk stratification approaches.